Cannabis use in Spanish patients with multiple sclerosis: Fulfilment of patients' expectations?

Martínez-Rodríguez, José Enrique; Munteis, Elvira; Carreño, Mar; Blanco, Yolanda; Roquer, Jaume; Abanades, Sergio; Graus, Francesc; Sáiz, Albert

doi:10.1016/j.jns.2008.06.037

Cited by 21 publications

(27 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Spain, 17.1% of 175 MS patients reported any recurrent consumption of marijuana to alleviate MS-related symptoms (Martínez-Rodríguez et al, 2008), which was similar to that observed in Canada (Clark et al, 2004). In the U.K., Chong et al (2006) found that 30% of 254 MS patients were those who started using marijuana because of MS, which was considerably higher than those observed in Canada (Clark et al, 2004) and Spain (Martínez-Rodríguez et al, 2008). In France, Leroux et al (2013) showed that 19.4% of 139 patients with cluster headache (CH) were those who had tried marijuana to treat CH symptoms.…”

Section: Resultssupporting

confidence: 58%

“…Four studies were from Canada (Clark et al, 2004; Furler et al, 2004; Storr et al, 2014; Ware et al, 2003) and one study each was from Spain (Martínez-Rodríguez et al, 2008), the U.K. (Chong et al, 2006), France (Leroux et al, 2013), and Australia (Degenhardt et al, 2015). In Canada, the prevalence of self-medication with marijuana was modestly similar across medical conditions, except for patients with HIV.…”

Section: Resultsmentioning

confidence: 99%

“…Furler et al (2004) found that among 104 Canadian patients with HIV (mean age: 42.7±9.3), 28.8% used marijuana to self-manage their symptoms in the past year. Two studies provided the estimates of self-medication with marijuana among MS patients in different European countries (Chong et al, 2006; Martínez-Rodríguez et al, 2008). In Spain, 17.1% of 175 MS patients reported any recurrent consumption of marijuana to alleviate MS-related symptoms (Martínez-Rodríguez et al, 2008), which was similar to that observed in Canada (Clark et al, 2004).…”

Section: Resultsmentioning

confidence: 99%

“…Two studies provided the estimates of self-medication with marijuana among MS patients in different European countries (Chong et al, 2006; Martínez-Rodríguez et al, 2008). In Spain, 17.1% of 175 MS patients reported any recurrent consumption of marijuana to alleviate MS-related symptoms (Martínez-Rodríguez et al, 2008), which was similar to that observed in Canada (Clark et al, 2004). In the U.K., Chong et al (2006) found that 30% of 254 MS patients were those who started using marijuana because of MS, which was considerably higher than those observed in Canada (Clark et al, 2004) and Spain (Martínez-Rodríguez et al, 2008).…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Prevalence, reasons, perceived effects, and correlates of medical marijuana use: A review

Park

2017

Drug and Alcohol Dependence

133

View full text Add to dashboard Cite

Background The use of marijuana for medical purposes is now legal in some U.S. states and other jurisdictions, such as Canada, and Israel. Despite the widespread legalization of medical marijuana globally, there is limited information on patterns and correlates of medical marijuana use (MMU). We conducted a literature review to assess prevalence, reasons, perceived effects, and correlates of MMU among adolescents and adults. Methods We searched peer-reviewed articles in English between January 1996 and August 2016 from several databases (PubMed, Google Scholar, Embase, CINAHL, and PsycINFO) using different combinations of keywords. Results A total of 25 articles met the inclusion criteria. In the U.S., national survey estimates of prescribed MMU was 1.1% among 12th graders and 17% among adults who reported past-year marijuana use. The reported prevalence of prescribed MMU ranged from <1.7% in Israeli cancer patients to 17.4% in American health care patients. The reported prevalence of self-medication with marijuana ranged from 15% in Canadian patients with chronic pain to 30% in British patients with multiple sclerosis. Pain was the most frequently endorsed reason for use. MMU appeared to provide symptom relief for a range of pain conditions, sleep disturbance, and anxiety symptoms, but it did not appear to provide sufficient relief of cluster headache symptoms. Non-medical marijuana use was a common factor associated with MMU across studies. Conclusion Either MMU or self-medication with marijuana was common, mainly due to pain management. Additional research is needed to evaluate temporal and causal associations of non-medical marijuana use with MMU.

show abstract

Section: Resultssupporting

confidence: 58%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence, reasons, perceived effects, and correlates of medical marijuana use: A review

Park

2017

Drug and Alcohol Dependence

133

View full text Add to dashboard Cite

show abstract

“…Prevalence of medicinal Cannabis use by individuals with MS is estimated at 14% in Nova Scotia, 17% in Spain and 22% in the UK (Clark, Ware et al 2004, Ware, Adams et al 2005, Martinez-Rodriguez, Munteis et al 2008). Given the critical role of circulating immune cells in MS and the immuno-modulatory actions of pCB on these cells, we sought to determine if Cannabis use differentially modulates three parameters: ex-vivo migration of circulating monocytes (Sexton 2012), quantity of cytokines and eCB released in serum.…”

Section: Introductionmentioning

confidence: 99%

Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters

et al. 2014

View full text Add to dashboard Cite

Cannabinoids affect immune responses in ways that may be beneficial for autoimmune diseases. We sought to determine whether chronic Cannabis use differentially modulates a select number of immune parameters in healthy controls and individuals with multiple sclerosis (MS cases). Subjects were enrolled and consented to a single blood draw, matched for age and BMI. We measured monocyte migration isolated from each subject, as well as plasma levels of endocannabinoids and cytokines. Cases met definition of MS by international diagnostic criteria. Monocyte cell migration measured in control subjects and individuals with MS were similarly inhibited by a set ratio of phytocannabinoids. The plasma levels of CCL2 and IL17 were reduced in non-naïve cannabis users irrespective of the cohorts. We detected a significant increase in the endocannabinoid arachidonoylethanolamine (AEA) in serum from individuals with MS compared to control subjects, and no significant difference in levels of other endocannabinoids and signaling lipids irrespective of Cannabis use. Chronic Cannabis use may affect the immune response to similar extent in individuals with MS and control subjects through the ability of phytocannabinoids to reduce both monocyte migration and cytokine levels in serum. From a panel of signaling lipids, only the levels of AEA are increased in individuals with MS, irrespective from Cannabis use or not. Our results suggest that both MS cases and controls respond similarly to chronic Cannabis use with respect to the immune parameters measured in this study.

show abstract

Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis

Filippini

Borrelli

Cinquini

et al. 2022

CDSR

View full text Add to dashboard Cite

Cannabis use in Spanish patients with multiple sclerosis: Fulfilment of patients' expectations?

Cited by 21 publications

References 15 publications

Prevalence, reasons, perceived effects, and correlates of medical marijuana use: A review

Prevalence, reasons, perceived effects, and correlates of medical marijuana use: A review

Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters

Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis

Contact Info

Product

Resources

About